GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate
Shots:
- The P-III trial will assess adjuvanted CoVLP formulation (two doses of 3.75µg- administered 21 days apart) vs PBO in ~30-000 subjects initially in healthy adults (18-65yrs.)- followed by elderly adults (65yrs.+) and adults with comorbidities
- The US FDA and Health Canada have approved the initiation of the P-III study based on the positive P-II results which are expected to be available in Apr’21.
- In parallel- Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants. The US FDA has granted FTD to the vaccine on Feb 17- 2021
Ref: Businesswire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com